Deferiprone‐associated myelotoxicity
- 1 November 1994
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 53 (5) , 298-301
- https://doi.org/10.1111/j.1600-0609.1994.tb01323.x
Abstract
Agranulocytosis developed in a 63-year-old patient with myelodysplasia 6 weeks after commencing treatment with the oral iron chelator deferiprone (L1, 1,2-dimethyl-3-hydroxypyrid-4-one, CP20) at a daily dose of 79 mg/kg. This was the 3rd case of agranulocytosis (neutrophils 0 x 10(9)/l) in clinical trials of L1 at the Royal Free Hospital. The neutrophil count recovered 7 days after stopping L1 and commencing G-CSF at a dose of 300 micrograms daily. Three other patients with milder degrees of neutropenia (neutrophils < 1.5 x 10(9)/l) have also been observed in our trials. The case histories of these 4 patients are described here; other reported cases of neutropenia or agranulocytosis are reviewed. Based on worldwide long-term clinical trials the incidence of agranulocytosis is about 1.6% and of neutropenia 2%.Keywords
This publication has 6 references indexed in Scilit:
- The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture systemBritish Journal of Haematology, 1994
- Differential toxicity of α‐keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitroEuropean Journal of Haematology, 1994
- Agranulocytosis in a Patient with Thalassaemia major during Treatment with the Oral Iron Chelator, 1,2-Dimethyl-3-Hydroxypyrid-4-0neActa Haematologica, 1993
- Efficacy and possible adverse effects of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major [see comments]Blood, 1992
- Long‐term trial with the oral iron chelator 1,2‐dimethy1‐3‐hydroxypyrid‐4‐one (L1) II. CLINICAL OBSERVATIONSBritish Journal of Haematology, 1990
- AGRANULOCYTOSIS AND THROMBOCYTOPENIA IN PATIENT WITH BLACKFAN-DIAMOND ANAEMIA DURING ORAL CHELATOR TRIALThe Lancet, 1989